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Abstract: Edible seaweeds have been consumed by Asian coastal communities since ancient times.
Fucus vesiculosus and Ascophyllum nodosum extracts have been traditionally used for the treatment
of obesity and several gastrointestinal diseases. We evaluated the ability of extracts obtained from
these algae to inhibit the digestive enzymes α-amylase and α-glucosidase in vitro, and control
postprandial plasma glucose levels in a mouse model of non-alcoholic steatohepatitis (NASH); a liver
disease often preceding the development of Type 2 diabetes (T2DM). This model was obtained by
the administration of a high-fat diet. Our results demonstrate that these algae only delayed and
reduced the peak of blood glucose (p < 0.05) in mice fed with normal diet, without changing the
area under the blood glucose curve (AUC). In the model of NASH, the phytocomplex was able to
reduce both the postprandial glycaemic peak, and the AUC. The administration of the extract in
a diet particularly rich in fat is associated with a delay in carbohydrate digestion, but also with a
decrease in its assimilation. In conclusion, our results indicate that this algal extract may be useful in
the control of carbohydrate digestion and absorption. This effect may be therapeutically exploited to
prevent the transition of NASH to T2DM.
Keywords: Ascophyllum nodosum; Fucus vesiculosus; nonalcoholic steatohepatitis; postprandial blood
glucose level
1. Introduction
Edible seaweed, an easily available food source, has probably been consumed by coastal
communities since the dawn of time, especially in Asia [1]. Seaweeds and their organic extracts
are known to contain several bioactive polysaccharides with numerous health benefits [2–8].
These polysaccharides cannot be completely digested by the human digestive system and represent a
source of dietary fiber, prebiotics, and other functional ingredients [9,10]. Soluble fiber can slow down
the digestion and absorption of nutrients by increasing the viscosity, thereby decreasing blood sugar
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levels and cholesterol [10]. Consistent with these observations, it has been reported that seaweed fiber
consumption is associated with a significant reduction of chronic diseases, such as diabetes, obesity, and
hypertension [11,12]. Recent studies have reported that fucoidan, a sulphated polysaccharide found in
many species of brown algae and seaweed, has numerous biological and pharmacological activities,
such as anti-proliferative, anti-inflammatory, and antiviral effects [13,14]. Algae extracts are considered
a good source of digestive enzyme inhibitors. In particular, they contain polyphenolic compounds,
such as bromophenols [15,16] and phlorotannins (PHTs) [5,17], which are well known α-glucosidase
inhibitors. The enzyme α-glucosidase, together with α-amylase, is a key enzyme in starch breakdown
and absorption. α-amylase is secreted from the pancreas and salivary glands [4], and catalyses the
cleavage of α-D-(1-4) glycosidic linkages of starch, amylose, amylopectin, glycogen, and various
maltodextrins, into shorter oligosaccharides, such as maltose and glucose [18,19]. α-glucosidase,
which is also located in the brush-border surface membrane of intestinal cells, activates the final step
of digestive processes by catalyzing the hydrolysis of complex carbohydrates and disaccharides to
absorbable monosaccharides, e.g., the release of glucose from maltose and/or sucrose [20]. It has been
reported that the inhibition of α-amylase and α-glucosidase can significantly lower the increase of
the blood glucose level, after a mixed carbohydrate meal, by delaying the absorption of glucose [21].
In Type 2 Diabetes (T2DM) patients, this approach proves to be more efficient than controlling insulin
secretion, since it is economic, convenient, and virtually prevents adverse drug reactions [22].
Nonalcoholic fatty liver disease (NAFLD) and its complication, nonalcoholic steatohepatitis
(NASH), have become the most common causes of chronic liver disease in Western countries, causing
considerable liver-related morbidity and mortality [23]. Evidence has accumulated that NAFLD
may precede the development of T2DM [24], since one hallmark of this liver condition is insulin
resistance, which is strongly associated with T2DM and abdominal obesity [24]. The subset of NAFLD
patients who have NASH is estimated to be about 15% of the European [25] and USA [26] populations.
Patients with NASH are at great risk of developing progressive liver disease and associated morbidity.
Interestingly, the prevalence of NASH significantly increases in high-risk populations, since NASH is
present in 25%–30% of patients with obesity or T2DM, and more than 35% of severely obese patients
who have T2DM [27–29].
In this study, we analyzed in vitro inhibitory activity on the digestive enzymes α-amylase
and α-glucosidase of, a commercially-available extract of Ascophyllum nodosum (egg wrack), and
Fucus vesiculosus (bladder wrack). Following this, we studied its effect on blood glucose levels after
starch ingestion in a mouse model of NASH, obtained by the administration of a high-fat diet (HFD)
for five weeks [30,31]. Since NASH is often associated with insulin resistance and T2DM, the objective
of this study was to ascertain whether seaweed extracts may be useful for glycaemic control in this
liver condition.
2. Materials and Methods
2.1. Chemicals and Reagents
Algae extract, commercially available under the trade name Gdue™ (Lot. N. 201400566),
was provided by Aesculapius (Brescia, Italy). The extract was prepared from the dried thallus of
Ascophyllum nodosum and Fucus vesiculosus, using a proprietary hot-water extraction process, followed
by a series of filtration and ultrafiltration processes, and completed by spray-drying. Alginates and
part of salts were removed during the process. The extract constituted a whole plant extract that
contained plant polyphenols (35.5%, as indicated in the certificate of analysis of the commercial
product), in addition to the algal polysaccharides (fibers) and minerals (iodine content <300 mg/kg).
Starch potato, dipotassium hydrogen phosphate (K2HPO4), potassium dihydrogen phosphate
(KH2PO4), sodium potassium tartrate, sodium hydroxide (NaOH), sodium chloride (NaCl),
glutathione, human salivary α-amylase, α-glucosidase, acarbose, p-nitrophenyl-α-D-glucopyranoside
(PNP-Gluc), and dinitrosalicylic acid (DNS), were obtained from Sigma Aldrich (St. Louis, MO, USA).
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2.2. NMR, HPLC-DAD, and GC-MS Analysis
For fingerprinting of the extract, 1H-NMR spectra were acquired using a Bruker Avance III
spectrometer (Billerica, MA, USA), operating at 400 MHz. The samples (100 mg) were weighted
and extracted with 1 mL of solvent (deuterated methanol or deuterated water) in an ultrasonic bath,
for 10 min. Samples were centrifuged (13,000 rpm) and the supernatant was transferred to an NMR
tube to be measured.
For the analysis of the polysaccharides, a Tosohaas PWXL 5000 9.4 × 300 mm was used as a
stationary phase. An Evaporative Light Scattering Detector (Agilent, Santa Clara, CA, USA) was
used to detect polysaccharides and a diode array detector was employed to observe absorption at
280 nm and the UV spectra. Elution was obtained using a mixture of 10 mM water and ammonium
formiate with 1% of acetonitrile. The flow rate was set at 1 mL/min. Different dextrans (1000, 5000,
80,000, 150,000 Da) were used to create a calibration between the molecular weight and retention times.
An estimation of the molecular weight of the polysaccharide fraction was obtained by comparing the
retention times with the standard dextrans.
GC-MS analysis of fatty acids was performed using a TRACE DSQ instrument (Thermo Scientific,
Waltham, MA, USA), with a chromatographic column DB5 (30 m × 0.25 mm × 0.25 pm) and a helium
gas flow rate of 1.2 mL/min. Chromatographic separation was performed using the following program:
100 ◦C for 4 min, an increase of 10 ◦C/min up to 200 ◦C, followed by an increase of 4 ◦C/min up to
260 ◦C. The algal sample was derivatized in order to detect the presence of the methyl esters of fatty
acids, and to compare this with methylated standards.
2.3. α-Amylase Activity Assay
A chromogenic 3,5-dinitrosalicylic acid (DNS) assay was employed to assess α-amylase activity, as
described by Roy et al. [32]. Potato starch was solubilized by boiling a 1% solution for 15 min in 20 mM
sodium phosphate (pH 6.9), containing 6.7 mM NaCl. The assay was carried out at 20 ◦C for 5 min in a
final volume of 2.1 mL with α-amylase (0.83 µg/mL) and soluble starch (47.6 µg/mL). The inhibitory
effect was measured by incubating 1 mL of substrate with 100 µL of algae extract solution at 20 ◦C for
10 min, prior to the assay. The reaction was stopped by adding 1 mL of DNS reagent and by boiling for
15 min. After the addition of 9 mL of water, the absorbance was read at 540 nm. The inhibitory activity
was calculated by means of the following formula:
% Inhibition =
A540Control − A540Test
A540Control
× 100
2.4. α-Glucosidase Activity Assay
α-Glucosidase activity was measured as the amount of p-nitrophenol released from PNP-Gluc [33].
The reaction was carried out at 37 ◦C for 20 min in 57 mM sodium phosphate buffer (pH
6.8 ◦C), containing 0.1 mM glutathione, 0.85 mM p-nitrophenylpyranoside (PNP)-Gluc, and 0.2 U
α-glucosidase. The reaction was stopped by adding 100 mM of sodium carbonate. The inhibitory effect
was measured by performing the reaction in the presence of 100 µL of algae extract or 100 µL of water
(control). The production of p-nitrophenol was quantified by measuring the absorbance at 400 nm,
and the inhibitory percentage was calculated by means of the following formula:
% Inhibition =
A400Control − A400Test
A400Control
× 100
2.5. Animals and Treatments
All experimental protocols were performed after authorization from the Animal Care and Use
Ethics Committee of the University of Padova and the Italian Ministry of Health (no. 80/2011-B,
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29 April 2011), and were in compliance with national and European guidelines for the handling and
use of experimental animals.
This investigation was performed on 60 C57BL/6J mice (8 ± 2 weeks old; Charles River
Laboratories, Calco (Lecco), Italy), which were randomly assigned to two experimental groups:
one fed with either standard, and the other with a high-fat diet (60/Fat, kcal from: 23.5% protein,
18.4% carbohydrate; 60.3% fat; Harlan Laboratories, Lesmo (Monza Brianza) Italy) for 35 days. Mice
had access to their diet and water ad libitum, were housed at 22 ◦C under a 12 h light/dark cycle, and
were kept as four specimens per cage, in the same room, by the same personnel. The body weight was
measured once a week. At day 35, all mice were fed by gavage with a 50%–50% starch (Sigma Aldrich,
St. Louis, MO, USA) and safflower oil solution (2 mL/kg·bw). Each group (standard and high-fat diet)
was divided into two subgroups: one served as a control and the other was treated with algae extract,
which was dissolved in the starch solution to reach a concentration of 7.5 mg/kg·bw. Blood glucose
levels were measured 30, 60, 120, and 180 min after gavage. Insulin levels were measured 0, 30, 60, and
180 min after gavage, by means of an ELISA kit (EMD Millipore, Darmstadt, Germany), following the
manufacturer’s instructions.
2.6. Histological Analysis
In order to evaluate the presence of fibrosis and/or steatosis, histological analyses were performed
on liver tissue samples fixed in 4% formaldehyde and embedded in paraffin. Five-micrometer sections
were stained with hematoxylin-eosin and picric acid-acid fuchsin (Van Gieson stain), using standard
techniques. Histological examinations of liver tissue were all performed by the same observer, who
was blinded from any information about the mouse. Images were obtained by means of a Leica DM
LB2 microscope equipped with a Leica DFC280 camera (Wetzlar, Germany).
2.7. Statistical Analysis
Statistical analyses were performed by means of the GraphPad Prism software, version 5
(GraphPad Software Inc., San Diego, CA, USA). Unless otherwise stated, the data are presented
as mean values ± S.E.M. A comparison of the experimental data obtained from the different groups
was made by one-way analysis of variance (ANOVA), followed by the Newman-Keuls post-hoc test,
or by the Student’s t-test, when appropriate. A comparison of the results obtained from the control
specimens and the animals treated with algae extract was performed by means of a Student’s t-test.
p < 0.05 was considered statistically significant.
3. Results
3.1. Phytochemical Fingerprint of the Algal Extract
As a first step for the profiling of the constituents present in the algal extract, 1H-NMR was
used. Two samples were prepared using deuterated methanol (MeOD) and deuterated water (D2O).
The 1H-NMR of the extract in MeOD (Figure S1) showed the presence of signals in the range of δ
0.85–5.00 ppm. No signals were visible in the field region ascribable to the aromatic protons, thus
supporting the argument that poor amounts of aromatic compounds bearing hydrogen atoms are
present, or that such constituents are not soluble in methanol. Further signals in the aliphatic region
support the presence of fatty acid derivatives, due to a broad triplet at δ 0.89 ppm which is ascribable
to the terminal methyl group, broad multiplets at δ 1.29–1.33 ppm typical of aliphatic CH2, and triplets
at δ 2.03 and 2.35 ppm which are ascribable to the CH2 nearby double bond and carbonyl function,
respectively. Further signals at δ 5.14 and 5.35 ppm can support the presence of double bonds in the
fatty acid chain. A singlet at δ 2.16 ppm can be assigned to the acetyl methyl group. Other signals in the
spectrum can also reveal the presence of sugar residues, namely the multiplets at δ 3.50–3.80 ppm and
the doublet of doublets at δ 4.16–4.35 ppm, which can be ascribed to CH2 of glycerol. Signals ascribable
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to ethanol presence are also visible as quartet at δ 2.33 ppm and triplet at δ 1.18 ppm, presented as a
relative amount of 2:3.
The 1H-NMR dissolved in D2O only showed signals in the range of δ 3.50–3.90 ppm, being
ascribable to oligosaccharide or sugar portions (Figure S2). Two small singlets at δ 8.40 and 6.45 ppm are
visible in the spectrum after water suppression with presaturation. Additionally, broad signals in the
range δ 6.00–6.35 ppm are visible and can be assigned to phenolic protons. A previous study indicates
that the signals in the 1H-NMR of phlorotannins are singlets in the range of δ 6.00–6.50 ppm [34]. In the
aliphatic region, minor signals are visible, namely a broad unresolved peak at 1.25 ppm, two singlets at
1.88 and 2.18 ppm, and some multiplets at δ 2.00–2.10 ppm. The number of these signals compared to
the sugar region is poor, as is clearly visible in Figure S2. Thus, the NMR analysis allowed us to observe
that the extract is mainly composed by saccharide derivatives and contains phloroglucinol derivatives.
HPLC with gel permeation revealed the presence of a large distribution of molecular weights for
carbohydrate derivatives (Figure S3), showing that there is a large abundance of small saccharides
(mono- and disaccharide), as well as large polysaccharides, in an estimated molecular weight range
of 50,000 to 150,000 Da. Moreover, there are further saccharides with molecular weights larger than
150,000 Da.
The presence of a high number of fatty acids in the extract, which has been suggested by 1H-NMR,
was confirmed by GC-MS analysis (Table 1). A typical chromatogram of this analysis is reported in
Figure S4.
Table 1. Retention time of methyl esters of fatty acids obtained by means of GC-MS analysis.
Retention Time (min) Methyl Ester of Fatty Acid
13.75 Methyl myristate
15.88 Methyl hexadecanoate
16.15 Methyl palmitate
18.58 Methyl linoleate
18.68 Methyl oleate
19.09 Methyl stearate
21.22 Methyl arachidonate
3.2. In Vitro Studies
The ability of algae components to inhibit α-amylase and α-glucosidase was tested by incubating
these enzymes with an increasing concentration of algae extract (0.04–30 µg/mL, n = 8 and
0.016–2 µg/mL, n = 9, respectively). Our results essentially confirmed the previous observation
of Roy et al. [32], that algae extract inhibits the in vitro activity of the two enzymes in a dose-dependent
manner. In particular, Figure 1 shows that the complete inhibition of α-amylase and α-glucosidase
activities can be reached at an algae extract concentration of 30 µg/mL and 2 µg/mL, respectively.
The IC50 values are reported in Table 2, compared to that of the standard inhibitor acarbose. As reported
in Table 2, the inhibitory potencies of algal mixtures on the two digestive enzymes are higher than
those of acarbose.
Table 2. IC50 values for α-amylase and α-glucosidase inhibition activity of algal extract and acarbose,
used as positive controls.
IC50 Value (µg/mL)
α-Amylase α-Glucosidase
Algal extract 1.49 ± 0.32 0.604 ± 0.004
Acarbose 130.2 ± 2.5 207.2 ± 5.3
Data are presented as means ± SD (n = 6). Results are obtained from three independent experiments, performed
in duplicate.
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Figure 1. Dose-dependent inhibition of the activity α-amylase (A) and α-glucosidase (B) by the algal
extract. Data are presented as means ± SD (n = 6). Results are obtained from three independent
experiments, performed in duplicate.
3.3. Induction of NASH
The effect of algae extract on plasma glucose levels was tested in vivo, in mice fed with either a
normal or high-fat diet (HFD mice). As clearly shown in Figure 2, the weight of HFD mice started to be
significantly higher than that of mice fed with a standard diet after three weeks of diet administration
(p < 0.05), and remained significantly higher until the day of sacrifice (p < 0.01).
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Figure 2. Increase of body weight of mice treated with standard (#, n = 30) and high-fat (, n = 30)
diet. Data are presented as mean ± SD. * p < 0.05 and ** p < 0.01 vs. mice treated with standard diet,
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Figure 3 shows that the mice fed a normal diet showed a normal liver histology, whil the mice
fed with HFD showed steatosis, lobular nflammation, and peri or al fibrosis (Ish k score = 1–2),
proving the presence of NASH. A significant increase in the deposition of abdominal fat after the
administration of HFD for five weeks (3.12% ± 0.81% vs. 1.18 ± 0.41% mice treated with HFD vs.
controls; p < 0.01) was observed. Glycated hemoglobin, which was measured in the animals of four
groups, was not significantly different (Data not shown).
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Figure 3. Representative photomicrographs of liver sections taken from a mouse treated with a standard
diet (hematoxylin-eosin staining, (A) magnification 10×), and a mouse treated with a high-fat diet,
stained with picric acid-acid fuchsin to detect liver fibrosis ((B) magnification 10×) or hematoxylin-eosin
to detect liver steatosis and flogosis ((C) magnification 40×).
3.4. In Vivo Studies
3.4.1. Mice Fed with a Normal Diet
Figure 4A shows that an oral intake of 7.5 mg/kg bw of algae extract reduced the initial increase
of the blood sugar level which is usually observed after a starch gavage (after 30 min, 197 ± 26 mg/dL
vs. 156 ± 27 mg/dL in controls and mice treated with algae extract, respectively; p < 0.05). There were
no differences in the blood glucose levels between the two groups of mice at 60 and 120 min, whereas
mice treated with the algae extract had significantly higher blood glucose levels (p < 0.05) 180 min after
gavage. The mean AUC0–180 values were virtually identical (19,785 vs. 19,980 mg·min/dL in mice
treated with algae extract and in controls, respectively).
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Figure 4. Postprandial plasma glucose (A) and insulin (B) levels in mice fed with standard diet treated
with vehicle (#, n = 15) or 7.5 mg/kg bw of algal extract (, n = 15). Data are presented as mean ±
SD.* p < 0.05 vs. mice treated with vehicle, Student’s t-test for unpaired data.
The plasma insulin curves are reported in Figure 4B. The peak value for insulin is reached 30 min
after gavage, and is significantly decreased by the administration of the algal extract. Accordingly,
a reduction was observed in the relative AUC0–180 value for the same mice (98 vs. 119 ng·min/mL in
mice treated with algae extract and in controls, respectively).
3.4.2. Mice Fed with HFD
Figure 5A shows that an oral intake of 7.5 mg/kg bw of algae extract significantly reduced the
increase in the blood sugar level which is normally seen after a starch gavage in mice fed with HFD.
The blood glucose levels were significantly lower in the mice treated with algae extract, with respect
to the controls, at every time point of the analysis. Accordingly, the mean AUC0–180 value in mice
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treated with algae extract was found to be lower than that of controls (20,906 vs. 26,689 mg·min/dL,
respectively).
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As shown in Figure 5B, in NASH mice, the insulin peak is reached 30 min after gavage and is
significantly decreased by the administration of the algal extract. AUC values confirm a reduction
in insulin secretion (114 vs. 132 ng·min/mL in mice treated with algae extract and in controls,
respectively).
4. Discussion
Preclinical and clinical studies have already demonstrated that algal extracts can reduce glucose
release from maltose and/or sucrose by inhibiting α-glucosidase [32,35]; an enzyme located in the
brush-border membrane of the small intestine. α-Glucosidase inhibitors, such as acarbose and
voglibose [36,37], are widely used for the treatment of T2D.
In this study, we investigated the in vitro inhibitory effect of a phytocomplex extracted from
Fucus vesiculosus and Ascophyllum nodosum, on both α-glucosidase and α-amylase; two intestinal
enzymes involved in carbohydrate digestion. The ability of a phytocomplex obtained from these algae
to inhibit both enzymes has already been demonstrated by Roy et al. [32], and was confirmed in this
research. In particular, the IC50 value of this extract for α-amylase inhibition was 10 to 1000-fold lower
than that reported for algae extracts prepared with solvents [17], fruit extracts [38], or polyphenols
obtained from other plants [39,40]. Moreover, the Ki value (6.0 × 10−8 M) indicated a strong affinity of
binding the algae inhibitory component to α-amylase. In this work, we confirmed these observations
by demonstrating that the inhibitory potencies of algal mixtures on the two digestive enzymes are
higher than that of acarbose; a prototypical α-glucosidase inhibitor. It has already been reported that
this inhibitory effect is due to the high content of different bioactive compounds in the algal extract,
in particular, phlorotannins (PHTs) [41,42] and fatty acids [43]. In order to ascertain the presence of
these algal components, we performed a fingerprint analysis of this extract, by which we confirmed
the presence of three main types of constituents: polysaccharides, polyphenolics, and fatty acids.
In order to ascertain the ability of this phytocomplex to reduce postprandial plasma glucose levels,
due to the inhibition of the two intestinal enzymes, we performed an in vivo study using mice fed with
either a normal or high-fat diet. The administration of HFD caused the accumulation of fat in rat livers,
which, together with the deposition of fibrotic tissue, is a prototypical manifestation of NASH [23].
The modulation of the postprandial glucose level was found to be different in the two groups of mice,
since the algae extract only delayed the appearance of the peak blood glucose level in mice fed with a
normal diet (30 min vs. 60 min after meal in controls and mice treated with algae, respectively), without
changing the area under the blood glucose curve. The blood glucose curves of mice treated with algae
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extract showed characteristics which are usually associated with low glycaemic index (GI) foods, i.e.,
a prolonged glucose absorption, since the blood glucose level of treated mice was significantly higher
after 180 min with respect to controls (p < 0.05). This finding suggests that algal phytocomplexes can
be used as dietary supplements, which, when taken before a meal, are able to slow down the rate of
carbohydrate digestion and assimilation, thereby changing the glycaemic response to high GI foods
into one typical of lower GI foods. In HFD mice, we demonstrated that this phytocomplex is able
to affect both the postprandial glycaemic peak, which was not delayed but considerably reduced
(p < 0.05), and the overall blood glucose level, which was lower at all measured time points, resulting
in a significantly lower AUC (p < 0.05). Therefore, the administration of this phytocomplex in a diet
particularly rich in fat is associated with a delay in carbohydrate digestion, but also with a decrease in
its assimilation. Since the insulin peaks decreased significantly (Figures 4B and 5B) in both healthy
and NASH mice after the administration of the algal mixture, we can conclude that the decrease in
plasma glucose levels is not due to an increase in insulin secretion, but more likely to a decrease of
glucose absorption. The effect of the chronic administration of this algal extract, and more details
about the mechanism(s) by which it affects postprandial plasma-glucose and insulin levels, and liver
damage in NASH mice, is currently being investigated in our laboratory.
The results obtained from animals also support the beneficial effect of extract obtained from
A. nodosum and F. vesiculosus in the modulation of postprandial blood glucose after a meal. This effect
cannot be explained solely by the presence of dietary fibers in the extract, since they are known to
only reduce the postprandial glycemic response when administered at higher doses (2.5 to 7.5 g in
humans) [44,45]. With the current administration, the amount of dietary fibers given to animals was
about 6 mg/kg·bw, which is equivalent to 420 mg in a 70-kg human being. Moreover, previous studies
investigating the effect of dietary fibers in mice have reported that glucose levels were significantly
lowered by the administration of at least 10% fiber in the diet [46]. These observations indicate that
the observed inhibitory activity is most likely due to the phytocomplex obtained from A. nodosum
and F. vesiculosus, and not to its dietary fiber content, since the amount of fiber administered in
this study was lower than 10% of the food intake. Apart from phlorotannins, which are known
inhibitors of digestive enzymes, as already stated in the Introduction, we identified, by means of
1H-NMR and GC-MS, the presence of fatty acids in the algal extract. As recently demonstrated
by Bingrui and collaborators [43], the fatty acids of an algal extract can inhibit α-glucosidase [43].
Therefore, the presence of phlorotannins and fatty acids, which are both digestive enzyme inhibitors
with different chemical and pharmacological characteristics, increases their pharmacological potency,
as demonstrated by the fact that the IC50 values of the algal extracts which we calculated are lower
than those previously reported in the literature for single components and acarbose [43].
In sum, the results of this study indicate that this algal extract may be useful in the control
of carbohydrate digestion and absorption. This effect is particularly evident in a mouse model of
NASH, obtained by the administration of a high-fat diet. Since NAFLD and NASH may precede the
development of T2DM, the use of this natural extract may be exploited therapeutically, to prevent or
delay this transition.
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/15/2/41/s1,
Figure S1: 1H-NMR spectrum of the algal extract in deuterated methanol, Figure S2: 1H-NMR spectrum of
the algal extract in deuterated water, Figure S3: HPLC with gel permeation, Figure S4: GC-MS chromatogram for
the identification of methylated fatty acids.
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